A Study of the Efficacy and Safety of RO7198457 in Combination With Atezolizumab Versus Atezolizumab Alone Following Adjuvant Platinum-Doublet Chemotherapy in Participants Who Are ctDNA Positive After Surgical Resection of Stage II-III Non-Small Cell Lung Cancer

NCT04267237 | Withdrawn Phase 2 FDA Drug

• 2 other identifiers: GO418362019-003449-14
• Study Type: interventional
• Target: N/A
• Locations: 0 countries
• Sites: N/A

Brief Summary

This study will evaluate the efficacy, safety, pharmacokinetics, immunogenicity and biomarkers of RO7198457 plus atezolizumab compared with atezolizumab alone in patients with Stage II-III non-small cell lung cancer (NSCLC) who are circulating tumor DNA (ctDNA) positive following surgical resection and have received standard-of-care adjuvant platinum-doublet chemotherapy.

Conditions

Non-small Cell Lung Cancer (NSCLC)

Keywords

Cancer vaccine; Neoantigen; Personalized; Atezolizumab; Vaccine; Immunotherapy; Anti-PDL1; Checkpoint Inhibitor; Personalized vaccine; Non-small cell lung cancer; NSCLC; Adjuvant

Outcome Measures

Primary Outcomes (1)

• Disease-free Survival (DFS)

  DFS as assessed by the investigator, is defined as the time from randomization to the date of first documented recurrence of NSCLC or occurrence of new primary NSCLC or death due to any cause, whichever occurs first.

  Up to 62 months

Secondary Outcomes (6)

• Percentage of Participants with Adverse Events (AEs) and Serious AEs (SAEs) determined according to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE v5.0)

  Up to 90 days after the final dose of study drug or until initiation of another systemic anti-cancer therapy (up to approximately 62 months)

• Plasma Concentrations of RNA at Specified Timepoints

  Arm B: Days 1, 8, 15, 22 of Cycle 1 (each cycle is 28 days), Day 1 of Cycle 2, 3, 5, 7, 9, 11 and treatment discontinuation (TD) visit (up to 12 months)

• Plasma Concentrations of (R)-N,N,N-trimethyl-2,3-dioleyloxy-1-propanaminium chloride (DOTMA) at Specified Timepoints

  Arm B: Days 1, 8, 15, 22 of Cycle 1 (each cycle is 28 days), Day 1 of Cycle 2, 3, 5, 7, 9, 11 and treatment discontinuation (TD) visit (up to 12 months)

• Maximum Serum Concentration (Cmax) of Atezolizumab at Specified Timepoints

  Arm A and Arm B: Day 1 of Cycles 1-4 (each cycle is 28 days) and at TD visit (up to 12 months)

• Minimum Serum Concentration (Cmin) of Atezolizumab at Specified Timepoints

  Arm A and Arm B: Day 1 of Cycles 1-4 (each cycle is 28 days) and at TD visit (up to 12 months)

Study Arms (2)

Atezolizumab

EXPERIMENTAL

Participants will receive atezolizumab on Day 1 of each 28-day cycle (Q4W) for 12 cycles.

Drug: Atezolizumab

Atezolizumab + RO7198457

EXPERIMENTAL

Participants will receive atezolizumab Q4W along with RO7198457 for 12 cycles.

Drug: Atezolizumab; Drug: RO7198457

Interventions

Atezolizumab DRUG

Atezolizumab 1680 mg will be administered by intravenous (IV) infusion on Day 1 of Cycles 1-12.

Also known as: Tecentriq

Atezolizumab; Atezolizumab + RO7198457

RO7198457 DRUG

RO7198457 will be administered by IV infusion at protocol-defined intervals for 12 cycles.

Atezolizumab + RO7198457

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age \>= 18 years;
• Resected Stage II-III Non-small Cell Lung Cancer (NSCLC) per American Joint Committee on Cancer staging criteria, 8th revised edition;
• Complete R0 resection of Stage II or III NSCLC prior to enrollment and adequate recovery from surgery;
• Pathological evaluation of mediastinal lymph nodes preoperatively or intraoperatively;
• ctDNA (circulating tumor DNA) identified in plasma after resection of Stage II-III NSCLC and prior to start of adjuvant platinum-doublet therapy, as determined by central testing;
• Treatment with at least two cycles of adjuvant platinum-doublet chemotherapy regimens for resected NSCLC;
• No unequivocal evidence of disease after surgery and adjuvant platinum-doublet chemotherapy, as assessed on imaging (computed tomography \[CT\] scan or magnetic resonance imaging \[MRI\]) within 28 days prior to randomization;
• Availability of adequate tumor material;
• Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1;
• Adequate hematologic and end-organ function;
• Negative HIV test at screening;
• Negative hepatitis B test at screening;
• Negative hepatitis C test at screening.

You may not qualify if:

• Participants with a known mutation in exons 18-21 of epidermal growth factor receptor (EGFR) or with a known anaplastic lymphoma kinase (ALK) or reactive oxygen species (ROS) alteration;
• History of malignancy other than disease under study within 5 years prior to enrollment, with the exception of malignancies with a negligible risk of metastasis or death, such as adequately treated carcinoma in situ of the cervix, non-melanoma skin cancer, localized prostate cancer, ductal carcinoma in situ, or Stage I uterine cancer;
• Induction and neoadjuvant systemic therapy prior to resection of NSCLC;
• Radiotherapy prior to or after resection of NSCLC;
• Prior systemic investigational therapy;
• Prior anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapeutic antibodies, or a cancer vaccine;
• Treatment with systemic immunostimulatory agents within 6 weeks or 5 drug elimination half-lives, prior to initiation of study treatment;
• Treatment with systemic immunosuppressive medication within 2 weeks prior to initiation of study treatment or anticipation of need for systemic immunosuppressive medication during study treatment;
• Treatment with monoamine oxidase inhibitors (MAOIs) within 3 weeks prior to initiation of study treatment or requirement for ongoing treatment with MAOIs;
• Active or history of autoimmune disease or immune deficiency;
• Known primary immunodeficiencies, either cellular or combined T-cell and B-cell immunodeficiencies;
• History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan;
• Significant cardiovascular disease;
• Major surgical procedure, other than for diagnosis or for resection of disease under current study, within 4 weeks prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the study;
• Known active or latent tuberculosis infection;

Sponsors & Collaborators

• Hoffmann-La Roche: lead

MeSH Terms

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

atezolizumab

Condition Hierarchy (Ancestors)

Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases

Study Officials

• Clinical Trials

  Hoffmann-La Roche

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Masking Details: Open label
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 7, 2020
• First Posted: February 12, 2020
• Study Start: March 31, 2021
• Primary Completion: September 30, 2025
• Study Completion: September 30, 2025
• Last Updated: February 4, 2021

Record last verified: 2021-02

Data Sharing

• IPD Sharing: Will share